John L. Higgins - Sep 12, 2024 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed
Stock symbol
TECH
Transactions as of
Sep 12, 2024
Transactions value $
$523
Form type
4
Date filed
9/16/2024, 04:18 PM
Previous filing
Jul 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $138K +6K +14.08% $22.95 48.6K Sep 12, 2024 Direct
transaction TECH Common Stock Tax liability -$137K -1.87K -3.86% $73.20 46.7K Sep 12, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -6K -100% $0.00 0 Sep 12, 2024 Common Stock 6K $22.95 Direct
holding TECH Stock Options (Right to Buy) 17K Sep 12, 2024 Common Stock 17K $21.84 Direct
holding TECH Stock Options (Right to Buy) 15.9K Sep 12, 2024 Common Stock 15.9K $25.30 Direct
holding TECH Stock Options (Right to Buy) 12.5K Sep 12, 2024 Common Stock 12.5K $31.26 Direct
holding TECH Stock Options (Right to Buy) 7.59K Sep 12, 2024 Common Stock 7.59K $44.96 Direct
holding TECH Stock Options (Right to Buy) 8.04K Sep 12, 2024 Common Stock 8.04K $50.41 Direct
holding TECH Stock Options (Right to Buy) 6.03K Sep 12, 2024 Common Stock 6.03K $63.92 Direct
holding TECH Stock Options (Right to Buy) 2.53K Sep 12, 2024 Common Stock 2.53K $128.81 Direct
holding TECH Stock Options (Right to Buy) 3.46K Sep 12, 2024 Common Stock 3.46K $73.94 Direct
holding TECH Stock Options (Right to Buy) 3.94K Sep 12, 2024 Common Stock 3.94K $61.51 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.